نتایج جستجو برای: liraglutide

تعداد نتایج: 1699  

Journal: :Molecular medicine reports 2014
Sai-Jun Zhou Lian Bai Lin Lv Rui Chen Chun-Jun Li Xiang-Yang Liu De-Min Yu Pei Yu

Accumulating evidence has implicated that liraglutide, one of the human glucagon‑like peptide‑1 (GLP‑1) analogues, elicits protective effects on diabetic nephropathy; however, the mechanism has yet to be fully elucidated. The present study aimed to assess the effect and underlying mechanisms of liraglutide in diabetic nephropathy. Wistar rats with streptozotocin‑induced diabetes mellitus were s...

2015
Jens J. Holst John B. Buse Helena W. Rodbard Sultan Linjawi Vincent C. Woo Trine Welløv Boesgaard Kajsa Kvist Stephen C. Gough

OBJECTIVE IDegLira is a novel, fixed-ratio combination of the long-acting basal insulin, insulin degludec, and the long-acting glucagon-like peptide-1 analog liraglutide. We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes. METHODS In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in ...

2016
Sten Madsbad

Currently, six glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for treating type 2 diabetes. These fall into two classes based on their receptor activation: short-acting exenatide twice daily and lixisenatide once daily; and longer-acting liraglutide once daily, exenatide once weekly, albiglutide once weekly and dulaglutide once weekly. The phase III trial of a seventh GLP-1RA...

2016
Sanjay Kalra

This commentary analyzes the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which has reported the cardiovascular benefits of liraglutide. It places the results of this seminal trial in the context of the evolution of diabetes care, compares them with other recently published cardiovascular outcome trials, and suggests novel mechanisms to...

Journal: :Journal of Analytical Science and Technology 2023

Abstract Liraglutide is a glucagon-like peptide-1 (GLP-1) analog that has been utilized for the treatment of type 2 diabetes mellitus. at higher dose also shows beneficial effects in weight loss, which prompted its widespread use as an anti-obesity drug. The potential liraglutide to treat Alzheimer’s disease and cognitive impairment suggested. Nevertheless, pharmacokinetics liraglutide, includi...

Journal: :BMC Cardiovascular Disorders 2009
Jens Kristensen Ulrik M Mortensen Morten Schmidt Peter Haubjerg Nielsen Torsten Toftegaard Nielsen Michael Maeng

BACKGROUND Glucagon-like peptide 1 (GLP1) analogues are promising new treatment options for patients with type 2 diabetes, but may have both potentially beneficial and harmful cardiovascular effects. This may also be the case for the analogues of GLP1 for clinical use. The present study examined the effect of treatment with liraglutide, a long-acting GLP1 analogue, on myocardial ischemia and re...

Journal: :The Journal of clinical endocrinology and metabolism 2017
Tuuli Sedman Eero Vasar Vallo Volke

Context Glucagon-like peptide-1 receptor agonists are popular antidiabetic drugs with potent glucose-lowering effects and low risk of hypoglycemia. Animal experiments and human data indicate that tolerance develops toward at least some of their effects (e.g., gastric motility). Whether tolerance develops toward the glucose-lowering effect of glucagon-like peptide-1 receptor agonists has never b...

Journal: :Cardiovascular Diabetology 2009
Sean D Sullivan Rafael Alfonso-Cristancho Chris Conner Mette Hammer Lawrence Blonde

BACKGROUND Poor control of type 2 diabetes results in substantial long-term consequences. Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and costs. We sought to estimate the long-term consequences of liraglutide and rosiglitazone both added to glimepiride. METHODS To estimate long-term clinical and economic consequences, we used the CORE diabete...

2017
Mahmoud M. Mosli Moaiad Elyas

BACKGROUND/AIM Intragastric balloon (IGB) is an effective and safe method of weight reduction. However, IGBs have been associated with a high rate of weight regain post removal. Accordingly, ways to improve sustained weight reduction including concomitant treatment with Glucagon-like peptide 1 (GLP-1) agonists have been proposed. This study aims to evaluate the effect of adding Liraglutide to I...

2017
Shao-Lian Wang Wen-Bin Dong Xiao-Lin Dong Wen-Min Zhu Fang-Fang Wang Fang Han Xin Yan

We performed a network meta-analysis to compare the efficacy of 12 single-drug regimens (Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, Sitaglitin, Exenatide, Liraglutide, Acarbose, Benfluorex, and Glipizide) in the treatment of type 2 diabetes mellitus (T2DM). Fifteen relevant randomized controlled trials (RCTs) were included; direct and indirect evidence from...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید